Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
BLFS 
BioLife Solutions Inc (BLFS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/06/2026: BLFS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $32.4
1 Year Target Price $32.4
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.39% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/06/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.22B USD | Price to earnings Ratio - | 1Y Target Price 32.4 |
Price to earnings Ratio - | 1Y Target Price 32.4 | ||
Volume (30-day avg) 9 | Beta 1.93 | 52 Weeks Range 19.10 - 29.62 | Updated Date 01/6/2026 |
52 Weeks Range 19.10 - 29.62 | Updated Date 01/6/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -3.2% | Operating Margin (TTM) -0.32% |
Management Effectiveness
Return on Assets (TTM) -0.73% | Return on Equity (TTM) -5.25% |
Valuation
Trailing PE - | Forward PE 476.19 | Enterprise Value 1091979818 | Price to Sales(TTM) 12.17 |
Enterprise Value 1091979818 | Price to Sales(TTM) 12.17 | ||
Enterprise Value to Revenue 10.9 | Enterprise Value to EBITDA 67.84 | Shares Outstanding 48148046 | Shares Floating 40831950 |
Shares Outstanding 48148046 | Shares Floating 40831950 | ||
Percent Insiders 1.74 | Percent Institutions 103.63 |
Upturn AI SWOT
BioLife Solutions Inc
Company Overview
History and Background
BioLife Solutions Inc. was founded in 2002. It has evolved from a provider of biopreservation media to a comprehensive solutions provider for the cell and gene therapy market. Key milestones include the development of proprietary preservation media, the expansion into cold chain logistics, and strategic acquisitions to broaden its product and service offerings.
Core Business Areas
- Biopreservation Media: Provides proprietary, serum-free, and protein-free media for the storage and transport of cells, tissues, and organs. This includes Hypo-Thermosolu00ae and Cryo-Shipperu2122 products.
- Cold Chain Solutions: Offers a suite of cold chain services, including temperature-controlled shipping solutions and bio-storage units, to ensure the integrity of biologics during transit and storage.
- Bioprocessing Tools: Acquires and integrates technologies that support cell and gene therapy manufacturing, such as automated thawing devices and thawing media.
Leadership and Structure
BioLife Solutions Inc. is led by a management team with extensive experience in the biotechnology and life sciences sectors. The company is structured to support its diverse product lines and service offerings, with dedicated teams for R&D, sales, marketing, and operations. The current CEO is Stuart Wilson.
Top Products and Market Share
Key Offerings
- Hypo-Thermosolu00ae: A proprietary, ready-to-use preservation medium designed to protect cells and tissues from cold shock and thermal stress during storage and transport. Competitors include various generic cell culture media suppliers and specialized biopreservation companies. Market share data is not readily available for this specific product as it is often sold as part of a broader solution.
- Cryo-Shipperu2122: A proprietary, phase-change material-based shipper that maintains a stable cryogenic temperature for extended periods without the need for dry ice. Competitors include other specialized cold chain logistics providers and shippers utilizing traditional dry ice or active cooling systems. Market share data is not readily available for this specific product.
- Sagau2122 automated thawing device: An automated device for thawing cryopreserved biological products, ensuring consistent and controlled thawing. Competitors include other manufacturers of laboratory equipment for biological sample handling and thawing.
Market Dynamics
Industry Overview
BioLife Solutions operates within the rapidly growing biopharmaceutical and cell and gene therapy markets. Key trends include increasing demand for advanced therapies, a growing need for specialized cold chain logistics, and the outsourcing of bioprocessing and storage services.
Positioning
BioLife Solutions is positioned as a key enabler for the cell and gene therapy market, providing critical solutions for preserving and transporting valuable biological materials. Its competitive advantages include proprietary preservation technologies, a comprehensive suite of cold chain solutions, and strategic acquisitions that expand its market reach and capabilities.
Total Addressable Market (TAM)
The TAM for cell and gene therapy logistics, biopreservation media, and related services is substantial and growing, estimated to be in the billions of dollars. BioLife Solutions is strategically positioned to capture a significant portion of this market by offering integrated solutions that address the unique needs of this specialized industry.
Upturn SWOT Analysis
Strengths
- Proprietary biopreservation media and cold chain technologies
- Integrated suite of products and services for cell and gene therapy
- Strong customer relationships in the biopharmaceutical industry
- Experienced management team
- Acquisition strategy to expand product portfolio and market reach
Weaknesses
- Reliance on a few key product lines
- Potential for competition from larger, established players
- Integration risks associated with acquisitions
- Manufacturing capacity constraints as demand grows
Opportunities
- Continued growth in the cell and gene therapy market
- Expansion into new geographic markets
- Development of new preservation and delivery technologies
- Partnerships with academic institutions and research organizations
- Increased demand for outsourced bioprocessing and logistics
Threats
- Regulatory changes impacting the biopharmaceutical industry
- Intensifying competition from new entrants and established companies
- Economic downturns affecting R&D spending by biotech companies
- Technological obsolescence of existing products
- Supply chain disruptions impacting raw material availability
Competitors and Market Share
Key Competitors
- Cryoport Inc. (CYRX)
- Avantor, Inc. (AVTR)
- Thermo Fisher Scientific Inc. (TMO)
Competitive Landscape
BioLife Solutions differentiates itself through its focus on integrated biopreservation and cold chain solutions specifically tailored for the cell and gene therapy market. While competitors like Cryoport are strong in logistics, and Thermo Fisher and Avantor offer broader scientific product portfolios, BioLife Solutions aims to provide a specialized, end-to-end solution for its target niche.
Major Acquisitions
TrakCel
- Year: 2022
- Acquisition Price (USD millions): 35
- Strategic Rationale: To integrate TrakCel's advanced cell and gene therapy manufacturing execution system (MES) with BioLife Solutions' existing offerings, creating a comprehensive platform for managing and tracking advanced therapies.
Global Cooling
- Year: 2022
- Acquisition Price (USD millions): 10
- Strategic Rationale: To expand BioLife Solutions' cold chain logistics capabilities and service offerings, further strengthening its position as a complete solutions provider.
Growth Trajectory and Initiatives
Historical Growth: BioLife Solutions has experienced significant historical growth, driven by the expanding cell and gene therapy market and its strategic acquisitions of complementary businesses. Revenue growth has been a consistent trend.
Future Projections: Future growth projections for BioLife Solutions are generally positive, supported by analysts' expectations of continued expansion in the cell and gene therapy sector. Expectations often include further revenue increases and potential improvements in profitability as the company scales its operations and benefits from its integrated offerings.
Recent Initiatives: Recent initiatives include strategic acquisitions to bolster its product and service portfolio, expansion of its sales and marketing efforts, and ongoing investment in research and development to enhance its existing technologies and explore new therapeutic applications.
Summary
BioLife Solutions Inc. is a well-positioned company in the growing cell and gene therapy market, offering critical biopreservation and cold chain solutions. Its integrated approach and recent strategic acquisitions enhance its competitive standing. While it faces strong competition, its specialized focus and proprietary technologies provide a solid foundation for continued growth. Management will need to focus on operational efficiency and managing integration risks from acquisitions.
Similar Stocks
Sources and Disclaimers
Data Sources:
- BioLife Solutions Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Market Research Reports
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Financial data and market share figures are estimates and subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioLife Solutions Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 1989-11-22 | CEO & Chairman Mr. Roderick de Greef | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 159 | Website https://www.biolifesolutions.com |
Full time employees 159 | Website https://www.biolifesolutions.com | ||
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.